Med Financial Statements From 2010 to 2025
| MBGNF Stock | USD 0.01 0.00 0.00% |
Check Med BioGene financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Med BioGene's main balance sheet or income statement drivers, such as , as well as many indicators such as . Med financial statements analysis is a perfect complement when working with Med BioGene Valuation or Volatility modules.
Med |
Med BioGene Company Current Valuation Analysis
Med BioGene's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Med BioGene Current Valuation | 251.67 K |
Most of Med BioGene's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Med BioGene is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Med BioGene has a Current Valuation of 251.67 K. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The current valuation for all United States stocks is 100.0% higher than that of the company.
Med BioGene Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Med BioGene's current stock value. Our valuation model uses many indicators to compare Med BioGene value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Med BioGene competition to find correlations between indicators driving Med BioGene's intrinsic value. More Info.Med BioGene is considered to be number one stock in return on asset category among its peers. It is rated below average in current valuation category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Med BioGene's earnings, one of the primary drivers of an investment's value.About Med BioGene Financial Statements
Med BioGene stakeholders use historical fundamental indicators, such as Med BioGene's revenue or net income, to determine how well the company is positioned to perform in the future. Although Med BioGene investors may analyze each financial statement separately, they are all interrelated. For example, changes in Med BioGene's assets and liabilities are reflected in the revenues and expenses on Med BioGene's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Med BioGene. Please read more on our technical analysis and fundamental analysis pages.
Previously, it was engaged in the life science business with a focus on the development and commercialization of genomic-based clinical tests for non-small-cell lung cancer. Med BioGene Inc. was incorporated in 2006 and is headquartered in Vancouver, Canada. Med Biogene operates under Diagnostics Research classification in the United States and is traded on OTC Exchange.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Med Pink Sheet
Med BioGene financial ratios help investors to determine whether Med Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Med with respect to the benefits of owning Med BioGene security.